about
Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseasesRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaHuman recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseasesRecombinant factor VIIa.Anticipated and unanticipated complications of severe dengue in a primigravida.Single center experience on dosing and adverse events of recombinant factor seven use for bleeding after congenital heart surgery.Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential.The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients.Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhageRecombinant factor VIIa as an adjunctive therapy for patients requiring large volume transfusion: a pharmacoeconomic evaluation.Management of bleeding emergencies: when to use recombinant activated factor VII.Management of warfarin-related intracerebral hemorrhage.Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective.Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa.rFVIIa in the treatment of persistent hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease.Use of recombinant activated factor VII to arrest uncontrolled bleeding: a case series.
P2860
Q24201303-1F00DDA8-C43A-4AD2-9671-2D8E4612817DQ24236583-ABC69AB1-D135-40AA-A650-814CBAF115A1Q24245204-BB6644FC-37AF-4EF9-975B-6C0C26834658Q24246238-BCF1DF5E-271C-46DE-8908-0CC8F08A29FBQ33363658-147779D6-715B-49B8-9DE3-F83C867CB042Q33428900-482B1611-DA3E-4681-8DDD-7271F828A77EQ34759669-93D29A80-7D1B-417D-88B7-DAFE5B7798BFQ35839531-3A4B0177-B0DC-4841-BF71-D98452B4E631Q35879063-F89BC837-383A-4C00-B430-66406634FA3BQ36150578-585E3E1E-66B3-4B26-80C6-79B8AF7F3AAFQ36256080-0454D25A-4905-4E97-AB35-BFA4D6CF9BEDQ36263655-6B4EBBDF-3322-4FB7-BF85-F009DE3F1FB5Q36349585-C2239F42-4601-445F-BEFF-6E31C329CA9CQ37083648-385E2AF2-1471-4FBE-A1B3-A389578BF5BFQ43055091-C94F710A-463D-4784-80FA-C71E219E3435Q45881934-0AD4BAA0-B883-442E-9F0C-D3AC6B201090Q47740197-52363270-7580-4E69-A1F3-2C42B3B54E8EQ50664916-B12F119B-99CA-4C5F-BC4A-B9859DEAC0D2
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Ongoing NovoSeven trials.
@ast
Ongoing NovoSeven trials.
@en
type
label
Ongoing NovoSeven trials.
@ast
Ongoing NovoSeven trials.
@en
prefLabel
Ongoing NovoSeven trials.
@ast
Ongoing NovoSeven trials.
@en
P1476
Ongoing NovoSeven trials.
@en
P2093
Elisabeth Erhardtsen
P2888
P304
P356
10.1007/S00134-002-1472-6
P478
28 Suppl 2
P577
2002-10-01T00:00:00Z